Your browser is no longer supported. Please, upgrade your browser.
Settings
ETNB 89bio, Inc. daily Stock Chart
ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-4.96 Insider Own- Shs Outstand13.79M Perf Week-4.65%
Market Cap336.15M Forward P/E- EPS next Y-3.95 Insider Trans- Shs Float13.56M Perf Month-0.24%
Income-63.50M PEG- EPS next Q-0.92 Inst Own- Short Float4.34% Perf Quarter-38.01%
Sales- P/S- EPS this Y-210.60% Inst Trans1.86% Short Ratio11.50 Perf Half Y-17.83%
Book/sh5.79 P/B4.28 EPS next Y-4.80% ROA- Target Price44.25 Perf Year-
Cash/sh6.31 P/C3.93 EPS next 5Y13.00% ROE- 52W Range14.00 - 47.25 Perf YTD-5.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.54% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low77.07% ATR2.50
Employees22 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)48.68 Volatility8.98% 10.55%
OptionableNo Debt/Eq0.00 EPS Q/Q-107.80% Profit Margin- Rel Volume0.51 Prev Close23.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume51.20K Price24.79
Recom1.70 SMA20-5.12% SMA50-1.48% SMA200-9.77% Volume26,099 Change5.53%
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is BIO89-100, an engineered glycoPEGylated analog of fibroblast growth factor 21 that is in proof of concept Phase 1b/2a clinical trial in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver diseases with a high risk of NASH. It also focuses on the development and commercialization of other therapies related to NASH, and other liver and cardio-metabolic diseases. The company was founded in 2018 and is headquartered in San Francisco, California.